• Türkçe
    • English
  • English 
    • Türkçe
    • English
  • Login
View Item 
  •   DSpace@MEF
  • Fakülteler
  • İktisadi İdari ve Sosyal Bilimler Fakültesi
  • Ekonomi | Economics
  • İİSBF, EB, Bildiri ve Sunum Koleksiyonu
  • View Item
  •   DSpace@MEF
  • Fakülteler
  • İktisadi İdari ve Sosyal Bilimler Fakültesi
  • Ekonomi | Economics
  • İİSBF, EB, Bildiri ve Sunum Koleksiyonu
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.
Advanced Search

PMS37 - health care cost burden and demographic distribution of patients diagnosed with psoriatic arthritis in the us medicare population

Thumbnail

View/Open

Konferans Dosyası (50.22Kb)

Access

info:eu-repo/semantics/openAccess

Date

2015

Author

Li, L
Mao, X
Shrestha, S
Başer, Onur
Yuce, H
Wang, L

Metadata

Show full item record

Citation

Li, L., Mao, X., Shrestha, S., Yuce, H., & Wang, L. (2015). Health care cost burden and demographic distribution of patients diagnosed with psoriatic arthritis in the us medicare population. Value in Health. 18, 3, p. 159.

Abstract

OBJECTIVES: To investigate the health care cost burden and demographic distributionof patients diagnosed with psoriatic arthritis (PSA) in the Medicare fee-for-service(FFS) Dataset. METHODS: A retrospective database analysis was performed usingthe 100% Medicare FFS Datasets from October 1, 2008 through December 31, 2012.Patients diagnosed with PSA were identified using International Classification ofDiseases, 9th Revision, Clinical Modification (ICD-9-CM) diagnosis code 696.0, andthe index date was the date of the initial diagnosis. All patients were required to havecontinuous medical and pharmacy benefits 1-year pre- and post-index date. Healthcare costs and utilization during the baseline (1 year before the diagnosis date) andfollow-up (1 year after the diagnosis date) periods were calculated. RESULTS: Usingthe aforementioned criteria, 11,324 PSA patients were identified. The average ageat diagnosis was 74 years, 66.10% of patients were women and almost 92.36% werewhite. The majority of patients resided in the South U.S. region (39.01%). Diabetes(33.84%), chronic obstructive pulmonary disease (29.04%) and cerebrovascular disease(17.36%) were the main comorbidities observed during the baseline period. Duringthe follow-up period, 62.96% of patients had inpatient admissions, 47.29% had emergency room visits, 91.67% had outpatient office visits, 91.67% had outpatient visitsand 58.03% had pharmacy visits, costing, on average, $23,960, $237, $5,015, $5,252and $7,335, respectively. The average total cost of PSA patients was $36,548. The fivemost commonly prescribed medications for PSA were methotrexate sodium (4.54%),prednisone (3.37%), levothyroxine sodium (2.59%), hydrocodone bit/acetaminophen(2.43%) and simvastatin (2.11%). CONCLUSIONS: PSA patient demographic and healthcare cost information was obtained and the most commonly prescribed PSA medications were identified.

Source

Value in Health

Volume

18

Issue

3

URI

https://hdl.handle.net/20.500.11779/628

Collections

  • Araştırma Çıktıları, WOS İndeksli Yayınlar Koleksiyonu [482]
  • İİSBF, EB, Bildiri ve Sunum Koleksiyonu [77]



DSpace software copyright © 2002-2015  DuraSpace
Contact Us | Send Feedback
Theme by 
@mire NV
 

 




| Instruction | Guide | Contact |

DSpace@MEF

by OpenAIRE

sherpa/romeo

Browse

All of DSpaceCommunities & CollectionsBy Issue DateAuthorsInstitution AuthorTitlesORCIDSubjectsTypeLanguageDepartmentCategoryPublisherAccess TypeThis CollectionBy Issue DateAuthorsInstitution AuthorTitlesORCIDSubjectsTypeLanguageDepartmentCategoryPublisherAccess Type

My Account

LoginRegister

Statistics

View Google Analytics Statistics

DSpace software copyright © 2002-2015  DuraSpace
Contact Us | Send Feedback
Theme by 
@mire NV
 

 


|| Guide|| Instruction || Library || MEF University || OAI-PMH ||

MEF University Library, İstanbul, Turkey
If you find any errors in content please report us

Creative Commons License
MEF University Institutional Repository is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 Unported License..

DSpace@MEF:


DSpace 6.2

tarafından İdeal DSpace hizmetleri çerçevesinde özelleştirilerek kurulmuştur.